Posted by Michael Wonder on 21 Dec 2017
Aeterna Zentaris announces FDA approval of Macrilen (macimorelin) for diagnosis of adult growth hormone deficiency
20 December 2017 - Aeterna Zentaris announced today that the U.S. FDA has granted marketing approval for Macrilen (macimorelin), an orally available ghrelin agonist, to be used in the diagnosis of patients with adult growth hormone deficiency.
The Company estimates that approximately 60,000 tests for suspected adult growth hormone deficiency are being conducted each year across the United States, Canada and Europe.
Aeterna Zentaris intends to make Macrilen (macimorelin) available commercially in the United States during the first quarter of 2018.
